49 completed, 22 terminated, 18 recruiting, 15 active not recruiting. 120 Phase 1, 53 Phase 2.
Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Biospecimen Collection, Pomalidomide - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 12 | 2026-08-26 | 2026-10-15 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Surzetoclax, Daratumumab, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 325 | 2025-07-23 | 2026-10-27 |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AbbVie | 602 | 2025-06-30 | 2026-10-19 |
| Pomalidomide as an Immune-enhancing Agent for the Control of HIV Pomalidomide 2 mg, Placebo, Aspirin 75 mg - HIV-1 Infection | Phase 1 / Phase 2 | Active not recruiting | University of Aarhus | 32 | 2025-05-13 | 2026-05-07 |
| Bioequivalence Study Comparing Two Pomalidomide 4 mg Capsule Formulations in Healthy Male Subjects Xetrane® (Pomalidomide) 4 mg Hard Capsule, Imnovid® (Pomalidomide) 4 mg Hard Capsule - Pomalidomide Bioequivalence Study in Healthy Volunteers | Phase 1 | Completed | Knight Therapeutics (USA) Inc | 34 | 2025-01-25 | 2026-07-10 |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma JNJ-79635322, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 276 | 2024-12-04 | 2026-09-25 |
| A Pilot Bioequivalence Study of Pomalidomide Pomalidomide 4 MG Oral Capsule - Bioequivalence Study | Phase 1 | Unknown | Megalabs | 10 | 2024-09-15 | 2023-09-28 |
| A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma Pomalidomide, Rituximab, Methotrexate - PCNSL | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 43 | 2024-08-31 | 2024-08-15 |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma AZD0305, Elranatamab, Pomalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 226 | 2023-12-05 | 2026-10-30 |
| First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors OT-A201, IMids, Bevacizumab - Hematological Malignancy, Solid Tumor | Phase 1 | Recruiting | Onward Therapeutics | 150 | 2023-07-10 | 2025-03-20 |
| Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas Vincristine, Prednisone, Doxorubicin - Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 25 | 2023-06-27 | 2026-08-25 |
| A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments Belantamab, Belantamab mafodotin, Pomalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 123 | 2023-06-14 | 2026-08-19 |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®) - Multiple Myeloma, Myeloma | Phase 1 | Recruiting | K36 Therapeutics, Inc. | 165 | 2023-02-22 | 2026-10-22 |
| A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 1 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-12 | 2026-01-29 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Belantamab Mafodotin-Blmf, Daratumumab, Pomalidomide - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 / Phase 2 | Not yet recruiting | Hellenic Society of Hematology | 48 | 2022-10-20 | 2022-10-17 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma Etentamig, Dexamethasone, Lenalidomide - Relapsed/Refractory Multiple Myeloma | Phase 1 | Active not recruiting | AbbVie | 283 | 2022-10-20 | 2026-08-14 |
Showing 20 of 120. Sign in to see all of them.
Multiple Myeloma (80) · Recurrence (19) · Neoplasms, Plasma Cell (13) · Neoplasms (7) · Immunoglobulin Light-chain Amyloidosis (4) · Lymphoma, Non-Hodgkin (4) · Burkitt Lymphoma (3) · Hematologic Diseases (3) · Hematologic Neoplasms (3) · Lymphoma, B-Cell (3) · Sarcoma, Kaposi (3) · Waldenstrom Macroglobulinemia (3) · Acquired Immunodeficiency Syndrome (2) · Blood Protein Disorders (2) · Leukemia, Myeloid, Acute (2)
Celgene (15) · National Cancer Institute (NCI) (8) · AbbVie (5) · Janssen Research & Development, LLC (5) · Mayo Clinic (5) · GlaxoSmithKline (4) · Amgen (3) · M.D. Anderson Cancer Center (3) · Sanofi (3) · Canadian Myeloma Research Group (2) · Massachusetts General Hospital (2) · Multiple Myeloma Research Consortium (2) · Oncotherapeutics (2) · PETHEMA Foundation (2) · Teva Branded Pharmaceutical Products R&D LLC (2)
United States (95) · Spain (21) · France (20) · Canada (19) · Australia (18) · Germany (14) · Japan (11) · United Kingdom (10) · Israel (9) · Italy (9) · Greece (7) · Poland (7) · Belgium (6) · China (6) · Netherlands (6)
Edward O'Mara, MD (3) · Ramya M Ramaswami, M.D. (3) · Andrew J. Yee, MD (2) · Han Tun (2) · James R Berenson, MD (2) · Amine Bensmaine, MD (1) · Amrita Krishnan (1)
PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 23243282, PMID 23370364, PMID 23417027, PMID 23954889, PMID 24421329, PMID 25482239, PMID 26384354, PMID 26932802, PMID 26943915, PMID 27267105, PMID 27269947, PMID 27381904, PMID 27863194, PMID 28461396, PMID 28637662, PMID 28684537, PMID 30262659, PMID 30352784, PMID 30862646, PMID 31113777, PMID 31969330, PMID 32078124, PMID 32171061, PMID 32501528, PMID 32898244, PMID 32956453, PMID 33112184, PMID 33682447, PMID 33730360, PMID 33980831, PMID 34050260, PMID 34385543, PMID 34559902, PMID 34862247, PMID 35876974, PMID 36763537, PMID 36882409, PMID 37352498, PMID 37393120, PMID 37559718, PMID 37783970, PMID 38177852, PMID 38826786
2023 (10), 2019 (3), 2018 (2), P30CA015083 (2), 2009 (1), 2014 (1), 2017 (1), P30CA006973 (1), P30CA043703 (1), U01CA070095 (1), U10CA031946 (1), U10CA180820 (1), UM1CA081457 (1), UM1CA186691 (1), UM1CA186704 (1)